Clinical Research Trials

Clinical trials help us learn more about new medications and allow us to discover new uses for approved medications.

Our neurologists conduct clinical trials to provide access to the most current, leading-edge treatment options.

Clinical trials help us discover new indications for approved medications, and help us learn more about new medications not yet approved by the FDA. Participating in a clinical trial can give patients access to treatments that might not otherwise be available. Patients who choose to participate must provide voluntary informed consent and meet all criteria for participation in the study.

Our neurologists conduct these trials as a way to provide access to the most current treatment options. Thanks to the voluntary participation of many patients, we have successfully conducted more than 100 clinical trials.

We have participated in clinical trials for multiple neurological conditions including diabetic neuropathy, epilepsy, essential tremor, migraine headache, multiple sclerosis, neuropathic pain, Parkinson’s disease, postherpetic neuralgia, sciatica, and spasticity due to MS.

Our Research Director, Susan Woodard, is a Certified Clinical Research Coordinator through the Association of Clinical Research Professionals.  She has more than 35 years of experience conducting trials, including more than 15 years conducting neurology trials.


These studies are currently available at Asheville Neurology Specialists for patients who qualify for participation. If you are interested in learning more about these studies or clinical trials, please contact Susan Woodard, CCRC at or 828-210-9311.


Biogen– Tysabri vs. placebo for 6 months of double blind followed by 6 months of open label Tysabri. Criteria: for patients with 4 or more seizures per month.

Xenon: 12 week double blind study with new seizure medication, followed by open label extension with new drug. Criteria: for patients with 4 or more seizures per month.

MS (Multiple Sclerosis)

Novartis – open label Siponimod for MS patients who are transitioning to a new agent, 6 months of open label medication provided.

Parkinson’s Disease

Pharma Two B – 12 week study of study drug vs. Mirapex vs. Azilect for early/new onset of  PD. Criteria: no previous exposure to PD treatment (or less than 4 weeks, > 2 months prior to study entry).